Background: OnabotulinumtoxinA is an efficacious treatment option for patients with various conditions. Although studies have reported on the efficacy of onabotulinumtoxinA, quality of life (QoL) data are limited. This study evaluated QoL in patients treated with onabotulinumtoxinA across various therapeutic indications. Methods: MDs on BOTOX Utility (MOBILITY) was a prospective, multicenter, observational Canadian study in patients initiating (naïve) or receiving ongoing (maintenance) onabotulinumtoxinA treatment. Health utility was the primary outcome measure and was obtained from the Short Form-12 Health Survey using the Short Form-6D at baseline, week 4 posttreatment, and up to five subsequent treatment visits. The safety cohort included patients who received ≥1 onabotulinumtoxinA treatment. Results: The efficacy cohort included 1062 patients; the majority were Caucasian, female, and on maintenance onabotulinumtoxinA treatment. Adult focal spasticity (n = 398), blepharospasm (n = 81), cerebral palsy (n = 22), cervical dystonia (n = 234), hemifacial spasm (n = 116), and hyperhidrosis (n = 211) patients were included. Baseline health utility was generally higher in maintenance versus naïve patients; however, naïve patients showed the greatest improvements over time. Health utility was generally maintained or trended toward improvement across all cohorts, including maintenance patients who had been treated for up to 22 years before study entry. Eighteen of 1222 patients (2%) in the safety cohort reported 28 treatment-related adverse events; eight were serious in four patients. Conclusion: MOBILITY is the largest prospective study to date to provide QoL data over a variety of therapeutic indications following treatment with onabotulinumtoxinA. Although the QoL burden varies by disease, data suggest that long-term treatment may help improve or maintain QoL over time.RÉSUMÉ: Améliorations concrètes et à long terme de la qualité de vie de patients ayant bénéficié d'un traitement thérapeutique d'onabotulinumtoxinA. Contexte : L'injection d'onabotulinumtoxinA est une option thérapeutique efficace pour des patients atteints d'affections variées. Bien que des études aient signalé son efficacité, les données portant sur la qualité de vie (QV) des patients traités demeurent limitées. La présente étude vise donc à évaluer, eu égard à diverses indications thérapeutiques, la QV de patients traités au moyen de l'onabotulinumtoxinA. Méthodes : MDs on BOTOX Utility (MOBILITY) est une étude canadienne multicentrique d'observation prospective ayant été menée chez des patients qui n'avaient reçu jusque-là aucun traitement d'onabotulinumtoxinA et chez des patients qui bénéficiaient de façon continue d'un tel traitement dû à un problème chronique. L'état de santé (health utility) a été défini comme le principal indicateur de résultat. Il a été déterminé à partir du SF-12 (Short Form-12 Health Survey) en utilisant comme référence le SF-6D (4 semaines de suivi post-traitement et jusqu'à cinq visites de suivi). La cohorte év...